Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Chugai Pharmaceutical Co., Ltd.    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai and DeNA Jointly Launch 'Ring Again,' a Rheumatoid Arthritis Disease Awareness Project

11/25/2020 | 09:56am EST

TOKYO - Chugai Pharmaceutical Co., Ltd. (Tokyo: 4519) and DeSC Healthcare, Inc. a subsidiary of DeNA Co., Ltd. (Tokyo: 2432) announced that they have jointly launched 'Ring Again,' a disease awareness project with the goal of early detection of rheumatoid arthritis.

In addition to the release of 'Magic Glasses,' a disease awareness animation on rheumatoid arthritis, and a short film titled 'Mother's Lipstick' (awarded 2016 Cannes Lions Bronze), Chugai has been working on disease awareness activities through various media such as public lectures and radio/newspapers, to appeal to a broad age range about the importance of early detection, early treatment, and medical care provided by rheumatologists. Despite limitations in its disease awareness activities due to COVID-19, Chugai has decided to start 'Ring Again,' using a new approach which involves collaboration with an IT company. Using a wedding ring, something that a person would wear every day, as a tool, we aim to achieve early treatment by gaining more people's understanding about rheumatoid arthritis and communicating the importance of early detection. To contribute to global healthcare and people's health, Chugai will continue to engage in disease awareness activities focusing on patients.

The mission of the DeNA Healthcare Business is 'making the shift from 'sick care' to 'healthcare' and lengthening healthy lifespans.' DeNA provides various healthcare services making use of the engagement science knowhow accumulated through its Game and Sports Business, with the goal of solving social issues in the healthcare space.

As part of disease awareness activities, DeNA has conducted the 'Blue Star Project,' in cooperation with Roche Diagnostics K.K, a clinical trial diagnostic drug and equipment manufacturer and distributor, since October 2019. The project aims at improving the uptake rate of screening of cervical cancer across Japan. Based on DeNA's abilities to deliver content including information that encourages people's awareness and supports changing behavior and in communication designing expertise, both of which have been accumulated in the internet business and Healthcare Business, DeNA has focused on communication activities in the past year, particularly with the use of Instagram. About 3,000 postings related to the project, with many positive comments on cervical cancer screening, had been collected from supportive followers, which eventually helped us to encourage patients to receive screening.

Based on these results, we will further optimize the activities in 'Ring Again' to target disease awareness of rheumatoid arthritis.

About 'Ring Again'

Rheumatoid arthritis is a progressive disease that causes inflammation in the synovial membrane wrapping the joints due to immunologic abnormalities, for which early detection and early treatment are important. Many people may think that the patients are mainly elderly; however, in fact, the disease was found to occur in people in their 30s to 50s, i.e., at their working age.

Considering this situation, we have launched a project in which a wedding ring worn every day is used as a trigger to help people find discomfort and stiffness in the fingers. This project therefore will support people in their 30s to 50s to find changes in the bodies in their daily lives. Our intention is to encourage people, regardless of whether they usually wear wedding rings or not, to become conscious of wedding rings to notice changes in their physical condition.

In particular, we have started a website (https://ringagain.jp/, Japanese only) specifically for 'Ring Again' on which a concept video has become available since Sunday, November 22, the day known as 'Good Married Couple Day.' Furthermore, we will send messages to promote correct understanding of rheumatoid arthritis using a wedding ring as a tool through our official Twitter account (@ring_again) and a variety of advertisements.

I-PRIMO, a store specializing in bridal rings, has also decided to participate in the 'Ring Again' project.

About Rheumatoid Arthritis

Rheumatoid arthritis is an autoimmune disease commonly developed in women in their 30s to 50s. The number of patients is estimated to be from 0.7 to 0.8 million in Japan and 23.7 million in the world1,2. It is a systemic disease that causes functional impairment including joint pain and deformities. Without proper treatment, the symptoms may worsen over time.

The introduction of biopharmaceuticals allows us to aim at achieving remission (a state where there are no symptoms) with medications in the treatment of rheumatoid arthritis. An increasing number of recent studies have demonstrated that proper treatment at an early disease stage can inhibit progression of bone/joint destruction3.

About Chugai

Chugai Pharmaceutical is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs.

About DeNA

DeNA (pronounced 'D-N-A') develops and operates a broad range of mobile and online services including games, live streaming, entertainment, healthcare, and other diversified offerings. Founded in 1999, DeNA is headquartered in Tokyo with over 2,000 employees. DeNA's aim is to delight and impact the world through the use of the internet and AI. DeNA Co., Ltd. is listed on the Tokyo Stock Exchange (2432).

Contact:

Tel: +81-(0)3-3273-0554

Fax: +81-(0)3-3281-6607

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD. -0.72% 5619 End-of-day quote.2.11%
DENA CO., LTD. 2.44% 1934 End-of-day quote.5.17%
ROCHE HOLDING AG 0.51% 318.2 Delayed Quote.2.51%
All news about CHUGAI PHARMACEUTICAL CO., LTD.
01/19CHUGAI PHARMACEUTICAL : Supports the Japan Climate Initiative's Calling to Raise..
AQ
01/13CHUGAI PHARMACEUTICAL : Conducts Digital Transformation in Manufacturing with IB..
AQ
01/12Japanese Shares Close Higher on Positive News About COVID-19 Treatment, Econo..
MT
01/11Drug makers help Nikkei scale fresh 3-decade high
RE
2020Chugai Obtains Approval for Expanded Use of FoundationOne CDx Cancer Genomic ..
AQ
2020CHUGAI PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
2020CHUGAI PHARMACEUTICAL THE : Launch of Chugai's New TV Commercial Featuring Erika..
AQ
2020PRESS RELEASE : European Commission approves Roche's Phesgo (fixed-dose combinat..
DJ
2020CHUGAI PHARMACEUTICAL : Osteoporosis Agent Edirol Obtains Regulatory Approval in..
AQ
2020CHUGAI PHARMACEUTICAL : in-licenses Antibody Cocktail for COVID-19 from Roche
AQ
More news
Financials
Sales 2020 768 B 7 400 M 7 400 M
Net income 2020 219 B 2 112 M 2 112 M
Net cash 2020 410 B 3 954 M 3 954 M
P/E ratio 2020 42,4x
Yield 2020 0,95%
Capitalization 9 237 B 89 207 M 89 022 M
EV / Sales 2020 11,5x
EV / Sales 2021 10,4x
Nbr of Employees 7 394
Free-Float 37,7%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | 4519 | JP3519400000 | MarketScreener
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 5 078,18 JPY
Last Close Price 5 619,00 JPY
Spread / Highest target 15,7%
Spread / Average Target -9,62%
Spread / Lowest Target -27,0%
EPS Revisions
Managers and Directors
NameTitle
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.2.11%89 858
JOHNSON & JOHNSON2.76%425 761
ROCHE HOLDING AG2.51%306 541
NOVARTIS AG2.34%219 658
MERCK & CO., INC.-0.76%205 388
PFIZER INC.-0.90%202 770